Post Hoc Analysis of Solriamfetol Efficacy in Obstructive Sleep Apnea Patients with Excessive Daytime Sleepiness Stratified by Disease Severity.
Changjun Su, Jiucheng Shen, Kaida Guo et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of a randomized controlled trial evaluated solriamfetol's efficacy in Chinese patients with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS), stratified by disease severity. At week 12, solriamfetol significantly increased mean sleep latency compared to placebo across all apnea hypopnea index (AHI) subgroups, with least squares mean differences of 12.133 min, 12.676 min, and 10.935 min for AHI < 5, 5 ≤ AHI < 30, and AHI ≥ 30, respectively.
Key findings
- Solriamfetol increased MWT sleep latency by 12.133 min for AHI < 5 (P < 0.0001).
- For AHI 5 ≤ 30, the increase in MWT sleep latency was 12.676 min (P < 0.0001).
- In the AHI ≥ 30 subgroup, MWT sleep latency increased by 10.935 min (P = 0.0001).
- Solriamfetol reduced ESS scores by -2.0 for AHI < 5 and -2.1 for AHI 5 ≤ 30.
Why it matters
The findings suggest that solriamfetol is effective in improving wakefulness in patients with OSA and EDS, regardless of the severity of their condition. This could enhance treatment options for managing excessive daytime sleepiness in this population.